May 8, 2018

About Us

LYNDRA THERAPEUTICS

REINVENTING MEDICINES FOR A HEALTHIER WORLD

team

Trish

Dr Patricia Hurter

CEO | President | Member of the Board
Jess

Jessica Ballinger

Chief Operations
Officer
Ray

Raymond
Knox

Chief Manufacturing Officer
Richard 2

Dr Richard Scranton

Chief Medical
Officer
Orn 3

Dr Örn Almarsson

Chief Technology
Officer
Abbey

Abigail
Jenkins

Chief Commercial & Business Officer
Susan

Susan
Birdsey

SVP, People &
Culture
Jen

Jennifer
McGovern

SVP, Alliance & Program Management
Mary

Dr Mary Christian

SVP, Regulatory, Quality & Compliance
Dana

Dana
Vittum

VP,
Finance
Tyler

Dr Tyler
Grant

Sr Director,
Engineering
Rose-LinkedIn Square

Dr Rosemary Kanasty

Director, Platform Discovery

Board of Directors

Catherine Reynolds 2020

Catherine B. Reynolds

Chair of the Board
amycentered

Amy
Schulman

Executive Chair of the Board | Co-Founder
Trish

Dr Patricia Hurter

CEO | President | Member of the Board
Zafi 2

Dr Zafrira Avnur

Member of the Board
boblanger

Dr Robert Langer

Co-Founder | Member of the Board
Gio Traverso

Dr Giovanni Traverso

Co-Founder| Member of the Board

Company advisors

ANDREW_2307

Dr Andrew Bellinger

Co-Founder | Advisor
Bernie

Dr Bernard Silverman

Advisor
Joga

Dr Joga Gobburu

Advisor
Ed Harrigan a

Dr Edmund Harrigan

Advisor
0 (2)

Dr Thomas Laughren

Advisor
Peter0

Dr Peter Belafsky

Advisor
0

Dr Ian Wilding

Advisor

Company Timeline

Founded on technology developed within the MIT lab  of Dr. Robert Langer in collaboration with the Bill & Melinda Gates Foundation
Platform and single agent preclinical in 2 species
($0.3 M NIH Grant)
Demonstrated gastric residence achievable with desired pharmacokinetics-single agent
($23 M Series A, $105 M AbbVie Partnership, $6 M NIH Grant(s), $4 M BMGF Grant) 
Demonstrated once-weekly dosage form can safely reside in the stomach with predictable pharmacokinetics – single agent
($18 M NIH Grant(s), $13 M BMGF Grant)
Demonstrated once-weekly dosage form can safely reside in the stomach with predictable pharmacokinetics – two agents in one capsule and preliminary food effects
($60 M Series B, $122 M Gilead Partnership, $19M NIH Grant, $3 M DoD Grant)
Expanded pipeline, repeat dosing, and food effects
($2M BMGF Grant, $1M NIH Grant)
Initiating pivotal studies, expanding clinical pipeline, and scaling up commercial manufacturing

 

 

 

 

investors & partners